STOCK TITAN

Beryl Capital and David Witkin File Schedule 13G/A Reporting No Holdings in ALLK

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Schedule 13G/A filed on behalf of Beryl Capital entities and David A. Witkin reports no beneficial ownership of Allakos Inc. The filing, covering Common Stock (CUSIP 01671P100) and referencing the event date 06/30/2025, lists Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin as reporting persons. Each reporting person disclaims beneficial ownership and the filing shows an aggregate amount of 0 shares (0%) for all listed filers. The document includes the issuer address, signatures dated 07/31/2025 by Andrew Nelson and David A. Witkin, a certification that the securities were acquired and held in the ordinary course of business and not to influence control, and Exhibit 99.1 (Agreement Regarding Joint Filing).

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Reporting persons disclose 0 shares (0%), indicating no current economic stake or voting influence in Allakos.

The Schedule 13G/A explicitly reports an aggregate beneficial ownership of 0 shares (0%) for Beryl Capital entities and David A. Witkin as of the 06/30/2025 event date. The filing includes the standard certification that holdings are in the ordinary course and not intended to influence control. From a market-impact perspective, the filing is neutral: it documents positions (or lack thereof) rather than a change in ownership or an intent to act as an activist investor.

TL;DR: Joint filing and certification present routine disclosure with no governance implications given reported 0% ownership.

The filing names the reporting chain and attaches an Agreement Regarding Joint Filing (Exhibit 99.1), and contains signed certifications dated 07/31/2025. Because each reporting person disclaims beneficial ownership and lists 0 shares, there is no material change to control or board influence disclosed. This is a procedural disclosure rather than a governance event.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Beryl Capital Management LLC
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer
Date:07/31/2025
Beryl Capital Management LP
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:07/31/2025
Beryl Capital Partners II LP
Signature:/s/ Andrew Nelson
Name/Title:COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:07/31/2025
David A. Witkin
Signature:/s/ David A. Witkin
Name/Title:Reporting person
Date:07/31/2025
Exhibit Information

Exhibit 99.1 - Agreement Regrding Joint Filing of Statement on Schedule 13D or 13G

FAQ

Who filed the Schedule 13G/A for Allakos (ALLK)?

The filing was made on behalf of Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin.

How many Allakos shares were reported as beneficially owned?

The Schedule 13G/A reports an aggregate amount of 0 shares, representing 0% of the class for each reporting person.

What date does the filing reference for the event requiring this statement?

The filing references the event date of 06/30/2025.

When was the Schedule 13G/A signed?

Signatures on the filing are dated 07/31/2025, signed by Andrew Nelson and David A. Witkin.

Does the filing state any intent to influence control of Allakos?

No. Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Allakos

NASDAQ:ALLK

ALLK Rankings

ALLK Latest News

ALLK Latest SEC Filings

ALLK Stock Data

29.63M
88.59M
Research and Development in Biotechnology
Pharmaceutical Preparations
Link
US
SAN CARLOS